- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02271152
FAST Mapping During Atrial Fibrillation
March 4, 2019 updated by: Vijay Chauhan, University Health Network, Toronto
Focal Electrical Source and Trigger Mapping During Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide with a prevalence of 8% in the elderly.
AF is responsible for frequent hospitalizations, stroke, heart failure and mortality.
AF catheter ablation is an important treatment strategy for patients suffering from AF, but the success rate remains low after conventional pulmonary vein isolation (PVI).
The mechanism perpetuating AF is poorly understood.
Focal electrical sources and triggers (FAST) may sustain AF in some patients, which makes them a potential therapeutic target for ablation.
However, finding FAST is very challenging due to complex nature of AF electrical signals.
In this study, the investigators will attempt to localize focal electrical sources and triggers (FAST mapping) in patients undergoing AF ablation using custom software that evaluates periodicity and waveform morphology.
Patients will be randomized to one of two AF ablation strategies, namely FAST mapping/ablation + PVI vs. PVI alone.
The investigators will determine which strategy leads to better clinical outcome postablation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All patients must be over the age 18 and have a clinical indication for their first catheter ablation of AF because of symptomatic AF.
- This will include patients with either high burden paroxysmal (>4 self-terminating episodes of AF within the last 6 months with two episodes lasting at least 6 hours within the last year) or persistent AF (lasting ≥7 days, but which can still be converted to sinus rhythm).
Exclusion Criteria:
The major exclusion criteria will include:
- long-standing persistent AF (ie. AF which cannot be converted to sinus rhythm, or where multiple attempts at restoring sinus rhythm have failed)
- rheumatic valvular disease
- hypertrophic cardiomyopathy
- uncorrected cardiac shunts (eg. secundum ASD)
- severe mitral regurgitation or mechanical mitral valve
- left atrial size >55 mm (echo derived parasternal long axis view).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: FAST ablation + PVI
FAST mapping and ablation will be performed in addition to PVI
|
|
|
Active Comparator: PVI
Pulnonary vein isolation will be performed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to first symptomatic atrial fibrillation recurrence postablation
Time Frame: 3 months postablation
|
3 months postablation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2015
Primary Completion (Actual)
February 1, 2019
Study Completion (Actual)
February 1, 2019
Study Registration Dates
First Submitted
October 18, 2014
First Submitted That Met QC Criteria
October 21, 2014
First Posted (Estimate)
October 22, 2014
Study Record Updates
Last Update Posted (Actual)
March 6, 2019
Last Update Submitted That Met QC Criteria
March 4, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-121
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Medtronic Cardiac Ablation SolutionsRecruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation | Atrial Fibrillation (AF)Australia, United States, France, Belgium, Switzerland, Czechia
-
China National Center for Cardiovascular DiseasesRecruitingAtrial Fibrillation Ablation | Atrial Fibrillation (AF) | Radiofrequency Catheter Ablation | Atrial Fibrillation Recurrent | Pulsed Field AblationChina
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
CortexAblacon, Inc.Active, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Boston Scientific CorporationRecruitingAtrial Fibrillation (AF) | Persistant Atrial FibrillationUnited States, Spain, Belgium, France, Netherlands, Germany, Hong Kong
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Boston Scientific CorporationRecruitingParoxysmal Atrial Fibrillation | Persistent Atrial FibrillationHong Kong, Czechia, Croatia, Taiwan
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Medtronic Cardiac Ablation SolutionsNot yet recruitingParoxysmal Atrial Fibrillation (PAF) | Persistent Atrial Fibrillation
-
University Medical Centre LjubljanaEnrolling by invitationPersistent Atrial Fibrillation | Persistent Atrial Fibrillation LongstandingSlovenia
Clinical Trials on FAST mapping and ablation
-
University Hospital Southampton NHS Foundation...Boston Scientific Corporation; AbbottCompleted
-
Kardium Inc.CompletedAtrial FibrillationGermany, Switzerland
-
Medtronic Cardiac Ablation SolutionsCompletedAtrial FibrillationUnited States, Czechia, Israel
-
University Hospital Southampton NHS Foundation...Biosense Webster, Inc.CompletedVentricular TachycardiaUnited Kingdom
-
Klinikum-FuerthUniversity of Trieste; Boston Scientific CorporationRecruitingRadiation Exposure | Catheter Ablation | Atrial Flutter TypicalGermany
-
Imperial College LondonCompletedAtrial TachycardiaUnited Kingdom
-
Medtronic Cardiac Ablation SolutionsCompletedAtrial Fibrillation | Ventricular Tachycardia | Atrial FlutterCzechia
-
Medtronic Cardiac Ablation SolutionsCompletedAtrial Fibrillation | Atrial FlutterLithuania
-
Volta MedicalNot yet recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Atrial ArrhythmiaFrance
-
Volta MedicalFortreaActive, not recruitingAtrial Fibrillation | Arrhythmias, Cardiac | Atrial ArrhythmiaFrance, Germany